BrainsWay Valuation
Is BWAY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BWAY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BWAY ($9.71) is trading below our estimate of fair value ($53.39)
Significantly Below Fair Value: BWAY is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BWAY?
Key metric: As BWAY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is BWAY's PE Ratio? | |
|---|---|
| PE Ratio | 123.2x |
| Earnings | US$1.50m |
| Market Cap | US$184.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.5x |
| Enterprise Value/EBITDA | 59.5x |
| PEG Ratio | 1.9x |
Price to Earnings Ratio vs Peers
How does BWAY's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 33.5x | ||
ZJYL Jin Medical International | 47.4x | n/a | US$148.3m |
SRTS Sensus Healthcare | 15.2x | 26.0% | US$143.9m |
PDEX Pro-Dex | 31.4x | 18.2% | US$159.7m |
ELMD Electromed | 39.9x | n/a | US$255.9m |
BWAY BrainsWay | 123.2x | 63.6% | US$673.6m |
Price-To-Earnings vs Peers: BWAY is expensive based on its Price-To-Earnings Ratio (123.2x) compared to the peer average (33.5x).
Price to Earnings Ratio vs Industry
How does BWAY's PE Ratio compare vs other companies in the US Medical Equipment Industry?
| 4 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
MHUA Meihua International Medical Technologies | 1.5x | n/a | US$15.40m |
PAVM PAVmed | 0.7x | -77.8% | US$9.78m |
RTSL Rapid Therapeutic Science Laboratories | 0.3x | n/a | US$18.99k |
UTRS Minerva Surgical | n/a | n/a | US$8.00 |
| 4 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: BWAY is expensive based on its Price-To-Earnings Ratio (123.2x) compared to the US Medical Equipment industry average (38.3x).
Price to Earnings Ratio vs Fair Ratio
What is BWAY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 123.2x |
| Fair PE Ratio | 61.1x |
Price-To-Earnings vs Fair Ratio: BWAY is expensive based on its Price-To-Earnings Ratio (123.2x) compared to the estimated Fair Price-To-Earnings Ratio (61.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Patterson Companies
US$1.9b
Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.
PDCO
US$21.49
7D
5.3%
1Y
-31.6%
Centene
US$31.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$60.00
7D
3.8%
1Y
-17.8%
Lantheus Holdings
US$6.3b
Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
LNTH
US$89.53
7D
12.7%
1Y
29.8%